GRAIL Inc. Ordinary Shares GRAL 深 沪
交易中 09-16 15:37:04 美东时间
14.045
-0.045
-0.32%
华盛通- 最 高14.16
- 今 开14.10
- 成交量 103.77万股
- 最 低 13.2575
- 昨 收 14.09
- 总市值 4.36亿
- 52周最高 21.47
- 市盈率 静 --
- 换手率 3.34%
- 52周最低 12.56
- 委 比 -89.57%
- 总股本 3104.91万
- 历史最高 21.47
- 量 比 1.30
- 振 幅 6.41%
- 历史最低 12.56
- 每 手 1
- 风险率 1.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Illumina wins legal battle over Grail deal in EU; avoids €432M fine
A top court in the EU on Tuesday ruled against the European Commission's decision to review Illumina's (NASDAQ:ILMN) 2021 acquisition of cancer test developer Grail (NASDAQ:GRAL), eliminating the €432...
09-03 19:10
监管里程碑事件！法院判定欧盟委员会在Illumina(ILMN.US)-Grail(GRAL.US)收购案中越权
在与欧盟委员会就Grail收购交易案得诉讼中，欧盟最高法院支持Illumina。
09-03 17:25
GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)
MENLO PARK, Calif., Aug. 30, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a...
08-31 05:55
GRAIL to focus on multi-cancer early detection; cuts workforce by 30%
After Tuesday's closing bell, GRAIL (NASDAQ:GRAL) said it would focus its resources going forward on its core multi-cancer early detection programs, resulting in a 30% reduction in headcount. In addit...
08-14 05:19
GRAIL shares are trading higher. The company Q2 financial results.
GRAIL shares are trading higher. The company Q2 financial results.
08-14 04:55
GRAIL to Announce Second Quarter 2024 Financial Results
MENLO PARK, Calif., July 31, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will ...
08-01 04:05
80亿美元估值黄粱梦一场，拖垮因美纳后Grail(GRAL.US)还能撑多久？
经过3年挣扎与拉扯，Illumina却最终在去年12月17日宣布将Grail剥离。而这家曾经的独角兽也开始了迟到4年的美股IPO并于今年6月25日正式登陆纳斯达克，然后给投资者上演了一出“首日大跌近20%”的戏码。
06-27 11:00
癌症检测产品供应商Grail(GRAL.US)今晚登陆纳斯达克 已从Illumina(ILMN.US)剥离
从生命科学公司Illumina分拆出来的癌症检测产品供应商Grail于周二在纳斯达克上市。
06-25 21:27
Grail to begin trading as Illumina completes spinoff
GRAIL (GRAL) will begin trading on the Nasdaq as a publicly-listed independent company on Tuesday, after Illumina (NASDAQ:ILMN) completed the spinoff of the cancer test developer following regulatory ...
06-25 19:36
Once Valued At Around $7B, Cancer Blood Test Developer Grail To Kickstart Trading On NASDAQ
Illumina spins off Grail, making Grail an independent public company. Shareholders receive one GRAIL share per six Illumina shares. Illumina retains a 14.5% stake.
06-25 19:17
